Rani Therapeutics Holdings (RANI)
US Market

Rani Therapeutics Holdings (RANI) Stock Price & Analysis


RANI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.92 - $14.90
Previous Close$5.44
Average Volume (3M)31.76K
Market Cap
Enterprise Value$234.55M
Total Cash (Recent Filing)$98.48M
Total Debt (Recent Filing)$30.21M
Price to Earnings (P/E)-4.2
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding25,295,159
10 Day Avg. Volume23,809
30 Day Avg. Volume31,757
Standard Deviation0.28
Financial Highlights & Ratios
Price to Book (P/B)3.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.80
Price Target Upside305.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Number of people who visit Rani Therapeutics Holdings websites
Desktop Users
Mobile Users


What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $4.92 and its highest was $14.90 in the past 12 months.
    What is Rani Therapeutics Holdings’s market cap?
    Currently, no data Available
    When is Rani Therapeutics Holdings’s upcoming earnings report date?
    Rani Therapeutics Holdings’s upcoming earnings report date is May 10, 2023 which is in 42 days.
      How were Rani Therapeutics Holdings’s earnings last quarter?
      Rani Therapeutics Holdings released its earnings results on Mar 22, 2023. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.401 by $0.051.
        Is Rani Therapeutics Holdings overvalued?
        According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Rani Therapeutics Holdings pay dividends?
          Rani Therapeutics Holdings does not currently pay dividends.
          What is Rani Therapeutics Holdings’s EPS estimate?
          Rani Therapeutics Holdings’s EPS estimate is -$0.47.
            How many shares outstanding does Rani Therapeutics Holdings have?
            Rani Therapeutics Holdings has 24,719,973 shares outstanding.
              What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
              Rani Therapeutics Holdings reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.401. Following the earnings report the stock price went down -6.891%.
                Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
                Currently, no hedge funds are holding shares in RANI


                Rani Therapeutics Holdings Stock Smart Score

                The Rani Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Rani Therapeutics Holdings

                Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.


                Top 5 ETFs holding RANI

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold RANI. The ETFs are listed according to market value of RANI within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Bakhu Holdings
                NGM Biopharmaceuticals
                Tarsus Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis